News | CT Angiography (CTA) | February 14, 2017

NICE Guidance Recommends HeartFlow FFRct Analysis for Patients With Stable Chest Pain

U.K. committee concludes technology is safe, highly accurate and cost-effective solution for non-invasive evaluation

HeartFlow FFRct Analysis, NICE guidance, U.K., United Kingdom, guidelines, stable chest pain

February 14, 2017 — The National Institute for Health and Care Excellence (NICE) in the United Kingdom recently issued guidance for use of the HeartFlow FFRct (fractional flow reserve computed tomography) Analysis to help determine the cause of stable chest pain in patients. Developed by HeartFlow Inc., the HeartFlow FFRct Analysis is the first non-invasive technology to provide insight into both the extent of coronary artery disease and the impact that disease has on blood flow to the heart, enabling clinicians to select an appropriate treatment.

NICE recommends the HeartFlow FFRct Analysis for patients with stable recent onset chest pain. Based on the evidence, it concluded the technology is safe, has a high level of diagnostic accuracy and may avoid the need for invasive coronary angiography. The committee further concluded that, when compared to all other tests, use of the HeartFlow FFRct Analysis could save the U.K. National Health Service approximately £214 per patient through avoiding unnecessary invasive tests and treatment.

The new guidance follows chest pain guidelines issued by NICE in November 2016, recommending non-invasive coronary CT angiography (cCTA) as the initial diagnostic test for patients with stable chest pain. NICE now recommends the HeartFlow FFRct Analysis as the most cost-effective option when additional information is needed by the clinician.

HeartFlow’s process starts with data from a standard, non-invasive cCTA. Leveraging deep learning, an advanced form of artificial intelligence, HeartFlow creates a personalized, 3-D model of each patient’s arteries. Powerful computer algorithms then solve millions of complex equations to simulate blood flow and assess the impact of blockages in the arteries. With this actionable information, physicians can determine the right course of action for each patient.

“The HeartFlow FFRct Analysis provides a definitive understanding of both the anatomical and functional findings, without any additional testing or risk for patients,” said Joseph Mills, M.D., Liverpool Heart and Chest Hospital. “Application of the Heartflow FFRct Analysis is likely to transform the quality of care we can provide for patients, ensuring the most accurate diagnosis and the best treatment plan, as well reducing the need for invasive coronary angiography – a procedure not without its risks.”

Read the article “Clinical Applications of FFR-CT.”

VIDEO: Early U.S. Experience With FFR-CT in Evaluating ED Chest Pain Presentation

Read the article “One-Year PLATFORM Trial Results Reinforce Benefits of FFR-CT.”

Related Content

Two examples of CT myocardial perfusion (CTP) imaging assessment software. Canon is on the left and GE Healthcare is on the right. Both of these technologies have been around for a few years, but there have been an increasing amount of clinical data from studies showing the accuracy of the technology compared to nuclear imaging, the current stand of care for myocardial perfusion imaging, and cardiac MRI. #SCCT #perfusionimaging 

Two examples of CT myocardial perfusion (CTP) imaging assessment software. Canon is on the left and GE Healthcare is on the right. Both of these technologies have been around for a few years, but there have been an increasing amount of clinical data from studies showing the accuracy of the technology compared to nuclear imaging, the current stand of care for myocardial perfusion imaging, and cardiac MRI.

News | CT Angiography (CTA) | March 16, 2020
March 16, 2020 — The Society of Cardiovascular Computed Tomography (SCCT) released a new...
New ESC Guideline Provides Class 1 Recommendation for Coronary CTA
News | CT Angiography (CTA) | September 17, 2019
The European Society of Cardiology (ESC) published new ...
HeartFlow Announces FDA Clearance for HeartFlow Planner
Technology | CT Angiography (CTA) | September 12, 2019
HeartFlow Inc. has obtained clearance from the U.S. Food and Drug Administration (FDA) for the HeartFlow Planner, a non...
Gallery | CT Angiography (CTA) | August 08, 2019 | Dave Fornell, Editor
This is a photo essay of the ca...
Videos | CT Angiography (CTA) | August 08, 2019
This is a quick video example of a cardiac computed tomography (CT) exam showing a Medtronic CoreValve transcatheter
Videos | CT Angiography (CTA) | August 08, 2019
This is an example of an automated calcium scoring software to speed review of coronary artery calcium (CAC) scoring
Siemens Go.Top cardiovascular edition CT scanner with its detachable tablets used by the tech to control the scanner so they can stay at the patient's side longer. #SCCT19

Siemens Go.Top cardiovascular edition CT scanner with its detachable tablets used by the tech to control the scanner so they can stay at the patient's side longer. (Photo by Dave Fornell)

Feature | CT Angiography (CTA) | August 06, 2019 | Dave Fornell, Editor
There were several interesting new trends in cardiovascular computed tomography (CT) imaging at the 2019...
Artificial Intelligence Improves Heart Attack Risk Assessment
News | CT Angiography (CTA) | August 06, 2019
When used with a common heart scan, machine learning, a type of artificial intelligence (AI), does better than...
Overlay Init